financetom
Business
financetom
/
Business
/
Bank of Marin Q3 profit beats estimates as interest margin expands
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bank of Marin Q3 profit beats estimates as interest margin expands
Oct 27, 2025 6:22 AM

Overview

* Bank of Marin Q3 net income $7.5 mln, reversing previous quarter's net loss

* Adjusted EPS for Q3 beats analyst expectations

* Company reports improved net interest margin and asset quality

Outlook

* Bank of Marin expects continued loan growth through 2025

* Company anticipates further credit quality improvements by year-end

* Bank plans additional repositioning activities to improve earnings

Result Drivers

* LOAN GROWTH - Accelerated loan growth while maintaining disciplined underwriting, contributing to improved asset quality

* ASSET QUALITY - Substantial reduction in classified loans and decline in non-accrual loans, with further improvements expected

* NET INTEREST MARGIN - Improved by 15 basis points due to securities repositioning and higher average loan rates

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $0.47 $0.42 (6

Adjusted Analysts

EPS )

Q3 EPS $0.47

Q3 $9.61

Adjusted mln

Net

Income

Q3 Net $7.52

Income mln

Q3 Net $28.20

Interest mln

Income

Q3 Net 3.08%

Interest

Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Novabay Pharmaceuticals Signs Definitive Agreement To Sell Its Avenova Assets
BRIEF-Novabay Pharmaceuticals Signs Definitive Agreement To Sell Its Avenova Assets
Sep 22, 2024
Sept 20 (Reuters) - NovaBay Pharmaceuticals Inc ( NBY ): * NOVABAY PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENT TO SELL ITS AVENOVA ASSETS * NOVABAY PHARMACEUTICALS INC ( NBY ) - TO SELL AVENOVA ASSETS TO PRN FOR $9.5 MILLION Source text for Eikon: Further company coverage: ...
Matador Resources to Raise $750 Million in Senior Notes Offering
Matador Resources to Raise $750 Million in Senior Notes Offering
Sep 22, 2024
08:07 AM EDT, 09/20/2024 (MT Newswires) -- Matador Resources ( MTDR ) said Friday it plans to offer $750 million of senior unsecured notes due 2033 in a private placement. The energy company said it plans to use the net proceeds from the placement to repay outstanding borrowings under its credit facility, including all of the $250 million debt under...
Regeneron, Sanofi Say Eosinophilic Esophagitis Drug Recommended for Children in EU
Regeneron, Sanofi Say Eosinophilic Esophagitis Drug Recommended for Children in EU
Sep 22, 2024
08:26 AM EDT, 09/20/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended the expanded approval of its eosinophilic esophagitis drug Dupixent to treat children 1 to 11 years old. Dupixent, a human monoclonal antibody developed using Regeneron's VelocImmune technology, is...
Merck Receives Positive EU CHMP Opinions for Keytruda in Gynecologic Cancers
Merck Receives Positive EU CHMP Opinions for Keytruda in Gynecologic Cancers
Sep 22, 2024
08:17 AM EDT, 09/20/2024 (MT Newswires) -- Merck ( MRK ) said Friday that it has received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use for its anti-PD-1 therapy Keytruda in two gynecologic cancer indications. The first opinion recommends Keytruda with carboplatin and paclitaxel as first-line treatment of advanced or recurrent endometrial carcinoma, while...
Copyright 2023-2026 - www.financetom.com All Rights Reserved